{
    "Trade/Device Name(s)": [
        "Alere\u2122 Influenza A & B Test"
    ],
    "Submitter Information": "Alere Scarborough, Inc.",
    "510(k) Number": "K133637",
    "Predicate Device Reference 510(k) Number(s)": [
        "K103610"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "GNX"
    ],
    "Summary Letter Date": "December 18, 2013",
    "Summary Letter Received Date": "November 27, 2013",
    "Submission Date": "November 4, 2013",
    "Regulation Number(s)": [
        "21 CFR 866.3330"
    ],
    "Regulation Name(s)": [
        "Influenza virus serological reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "virology"
    ],
    "Analyte(s)": [
        "Influenza A nucleoprotein antigen",
        "Influenza B nucleoprotein antigen"
    ],
    "Specimen Type(s)": [
        "Nasal swab"
    ],
    "Specimen Container(s)": [
        "Coated Reaction Tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Alere Influenza A & B Test Strip"
    ],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic membrane assay",
        "Lateral flow immunoassay"
    ],
    "Methodologies": [
        "Qualitative antigen detection"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Strip test"
    ],
    "Document Summary": "FDA 510(k) summary for Alere\u2122 Influenza A & B Test using lateral flow immunochromatographic assay for detection of influenza A and B nucleoprotein antigens in nasal swab specimens.",
    "Indications for Use Summary": "Qualitative detection of influenza A and B nucleoprotein antigens in nasal swab specimens from symptomatic patients to aid in rapid differential diagnosis of influenza A and B infections; negative results are presumptive and should be confirmed by cell culture or FDA-cleared molecular assay.",
    "fda_folder": "Microbiology"
}